The EU AI in antibody generation market is undergoing a considerable surge, driven primarily by increasing investments in biotechnology and a greater focus on personalized medicine. Experts foresee substantial advancements in medicinal antibody development utilizing artificial intelligence, particularly within fields like oncology and immunotherape